#NewAseBioAlly | "AseBio is a key reference point in Spain’s biotechnology ecosystem"

AseBio. What does your company's work bring to the table and what is its strength?

Lander Elkoro. At IMCD, we provide high value-added solutions through the distribution of specialty chemicals and ingredients, connecting leading manufacturers with companies developing innovations in key sectors such as Biopharmaceuticals and Biotechnology.

Our strength lies in our deep technical market knowledge, a global network with local reach, and a strong commitment to sustainability and innovation. With highly skilled teams, we support our partners throughout the entire development process—from the initial idea to industrial implementation.

AseBio. What is AseBio for you?

Lander Elkoro. For us, AseBio is a key reference point in Spain’s biotechnology ecosystem. It acts as a catalyst for collaboration, innovation, and visibility across the sector.

For a company like IMCD, specialized in the distribution of high value-added ingredients and specialty chemicals, being part of AseBio represents a strategic opportunity to strengthen our presence in the biotech field, identify new synergies, and gain access to critical insights on market trends, regulatory frameworks, and innovation policies. It also allows us to build partnerships with companies and institutions leading scientific and technological development, while sharing our technical expertise and global experience to help bring new solutions to the market in an efficient and sustainable way.

AseBio. When did you first hear about AseBio?

Lander Elkoro. We first became aware of AseBio several years ago as part of our strategy to engage with the key players in the Spanish biotech ecosystem. Since then, we have closely followed its development and its role as a driver of opportunities and as a representative voice before institutions and society.

AseBio. What do you expect from being part of an association like AseBio?

Lander Elkoro. We hope to build strong, collaborative relationships with companies, research centers, and start-ups in the sector.

We aim to actively contribute our expertise and capabilities to tackle common industry challenges while identifying new opportunities for joint innovation.

Moreover, we see AseBio as an ideal forum to promote knowledge, internationalization, and the strategic positioning of the Spanish biotech sector—goals we fully share as a multinational with a strong presence in the country.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Lander Elkoro. One of the major challenges in the biotech sector is bridging the gap between research and industrial application.

For IMCD, our challenge is to continue being a strategic partner for our customers and principals by enabling access to emerging technologies and high value-added specialty chemicals, thus contributing to the sustainability of the entire value chain.

We aim to be the bridge that connects science and our represented companies with the market.